Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2005 Nov;66(6):600–612. doi: 10.1016/j.curtheres.2005.12.010

Effects of metabolic and myocardial microcirculatory abnormalities on the pathogenesis of cardiac autonomic neuropathy in type 2 diabetes mellitus: A prospective study in Japanese patients*

Hiromi Komori 1,*
PMCID: PMC3966002  PMID: 24678078

Abstract

Background:

In diabetic patients, cardiac autonomic neuropathy is an important factor affecting prognosis. Whether this condition in diabetic patients is caused directly by neurovisceral metabolic disorder and/or indirectly by micro circulation remains to be clarified.

Objective:

The aim of this study was to determine whether cardiac sympathetic nerve dysfunction can be detected using adenosine triphosphate (ATP) testing, while also investigating the effects of metabolic and/or myocardial microcirculatory abnormalities on the pathogenesis of cardiac autonomic nerve dysfunction in patients with type 2 diabetes mellitus (DM-2) in Japan.

Methods:

This prospective study was performed at the Division of Diabetology Department of Internal Medicine, Toho University, Ohashi Hospital, Tokyo, Japan. Patients aged ≥ 18 years with DM-2 with no abnormalities on electrocardiography (ECG) or echocardiography were enrolled. An ATP thallium (Tl)-201 myocardial scintigraphy test (ATP test) and iodine (I)-123 metaiodobenzylguanidine (MIBG) scintigraphy were performed. ATP was administered by continuous IV infusion over 6 minutes at 0.16 mg/kg · min. Five minutes after the ATP infusion was started, T1-201 111 MBq IV was administered. Single-photon emission computed tomography (SPECT) imaging was begun immediately after the end of ATP infusion and was completed 3 hours after stress to show washout from stress to rest. I-123 MIBG 111 MBq IV was administered. A planar image from the front side and a SPECT image (early phase) was obtained 15 to 30 minutes later. After 3 hours, a planar image from the front side and a SPECT image (late phase) were obtained to show washout from stress to rest. The mean TI washout rate (ATP-WR) and heart-to-mediastinum (H/M) ratio in the late-phase scintigraphic images and the washout rate of MIBG (MIBG-WR) in the left ventricle was determined. The correlations of these measurements with the mean values of glycosylated hemoglobin (HbA1c) and fasting plasma glucose obtained from monthly measurements over the previous 6 and 24 months were determined.

Results:

A total of 25 patients were enrolled (13 men, 12 women; mean [SD] age, 59.86 [8.28] years). Significant negative correlations between both ATP-WR and MIBG-WR and HbA1c were found (r = -0.52 [P = 0.02] and −0.47 [P = 0.03], respectively). Although no correlation was found between ATP-WR values and the early phase H/M ratio, a significant positive correlation was observed between ATP-WR and H/M ratio (r = 0.54; P = 0.02).

Conclusions:

In the present study in Japanese diabetic patients without subjective signs of coronary artery disease and without abnormalities on ECG or echocardiography, ATP-WR, an indicator of myocardial blood flow, was correlated with myocardial sympathetic nerve dysfunction and 24-month glycemic control. However, sympathetic nerve dysfunction was not correlated with 24-month glycemic control.

Key words: cardiac sympathetic nervous dysfunction, ATP T1-201 myocardial scintigraphy, I-123 metaiodobenzylguanidine scintigraphy, glycemic control

Full Text

The Full Text of this article is available as a PDF (1.6 MB).

Footnotes

*

This report was presented in abstract form at the 17th International Diabetes Federation Congress, November 2000, Mexico City, Mexico.

References

  • 1.Ewing D.J., Campbell I.W., Clarke B.F. The natural history of diabetic autonomic neuropathy. Q J Med. 1980;49:95–108. [PubMed] [Google Scholar]
  • 2.Rathmann W., Ziegler D., Jahnke M. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med. 1993;10:820–824. doi: 10.1111/j.1464-5491.1993.tb00173.x. [DOI] [PubMed] [Google Scholar]
  • 3.Ewing D.J., Campbell I.W., Clarke B.E. Mortality in diabetic autonomic neuropathy. Lancet. 1976;1:601–603. doi: 10.1016/s0140-6736(76)90413-x. [DOI] [PubMed] [Google Scholar]
  • 4.Stevens M.J., Raffel D.M., Allman K.C. Cardiac sympathetic dysinnervation in diabetes: Implications for enhanced cardiovascular risk. Circulation. 1998;98:961–968. doi: 10.1161/01.cir.98.10.961. [DOI] [PubMed] [Google Scholar]
  • 5.Tamaki N. Medicalsens; Tokyo, Japan: 1998. Basis and Clinical of Cardiac Nuclear Medicine-Modern Methods and Clues to Clinical Applications of Cardiac Nuclear Medicine. [in Japanese] [Google Scholar]
  • 6.Mantysaari M., Kuikka J., Mustonen J. Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [123I] metaiodobenzylguanidine. Diabetes. 1992;41:1069–1075. doi: 10.2337/diab.41.9.1069. [DOI] [PubMed] [Google Scholar]
  • 7.Merlet P., Valette H., Dubois-Rande J.L. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471–477. [PubMed] [Google Scholar]
  • 8.Baba M. Gendaiiryo-sha; Tokyo, Japan: 2001. Diabetic Neuropathy: Diagnosis and Examination of Diabetic Neuropathy; pp. 45–55. [in Japanese] [Google Scholar]
  • 9.Green D.A., Sima A.A.F., Stevens M.J. Complications: Neuropathy, pathogenic considerations. Diabetes Care. 1992;15:1902–1925. doi: 10.2337/diacare.15.12.1902. [DOI] [PubMed] [Google Scholar]
  • 10.Clark C.M., Jr, Lee D.A. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med. 1995;332:1210–1217. doi: 10.1056/NEJM199505043321807. [published correction appears in N Engl J Med. 1995;333:810] [DOI] [PubMed] [Google Scholar]
  • 11.Green D.A., Lattimer S.A., Sima A.A. Sorbitol, phosphoinositides, and sodium-potassiumATPase in the pathogenesis of diabetic complications. N Engl J Med. 1987;316:599–606. doi: 10.1056/NEJM198703053161007. [DOI] [PubMed] [Google Scholar]
  • 12.Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315–1321. doi: 10.1056/NEJM198805193182007. [DOI] [PubMed] [Google Scholar]
  • 13.Muller H.K., Kellerer M., Ermel B. Prevention by protein kinase C inhibitors of glucose-induced insulin-receptor tyrosine kinase resistance in rat fat cells. Diabetes. 1991;40:1440–1448. doi: 10.2337/diab.40.11.1440. [DOI] [PubMed] [Google Scholar]
  • 14.Abbott R.D., Donahue R.P., Kannel W.B., Wilson P.W. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA. 1988;260:3456–3460. [published correction appears in JAMA. 1989;261:1884] [PubMed] [Google Scholar]
  • 15.Dortimer A.C., Shenoy P.N., Shiroff R.A. Diffuse coronary artery disease in diabetic patients: Fact or fiction? Circulation. 1978;57:133–136. doi: 10.1161/01.cir.57.1.133. [DOI] [PubMed] [Google Scholar]
  • 16.Butler R., Macdonald T.M., Struthers A.D., Morris A.D. The clinical implications of diabetic heart disease. Eur Heart J. 1998;19:1617–1627. doi: 10.1053/euhj.1998.1284. [DOI] [PubMed] [Google Scholar]
  • 17.Kahn J.K., Zola B., Juni J.E., Vinik A.I. Radionuclide assessment of left ventricular diastolic filling in diabetes mellitus with and without cardiac autonomic neuropathy. J Am Coll Cardiol. 1986;7:1303–1309. doi: 10.1016/s0735-1097(86)80150-4. [DOI] [PubMed] [Google Scholar]
  • 18.Wheeler T., Watkins P.J. Cardiac denervation in diabetes. BMJ. 1973;4:584–586. doi: 10.1136/bmj.4.5892.584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Ewing D.J., Martyn C.N., Young R.J., Clarke B.F. The value of cardiovascular autonomic function tests: 10 Years experience in diabetes. Diabetes Care. 1985;8:491–498. doi: 10.2337/diacare.8.5.491. [DOI] [PubMed] [Google Scholar]
  • 20.Ito T., Hatakeyama S., Azuma S. Evaluation of cardiac sympathetic nerve dysfunction using 123 I metaiodobenzylguanidine (MIBG) scintigraphy in patients with noninsulin-dependent diabetes mellitus. Kinki Central Hospital Med J. 1998;9:9–14. [in Japanese] [Google Scholar]
  • 21.Taniguchi I., Mochizuki M. Microcirculatory disorder of diabetic heart. Heart View. 1999;3:621–626. [Google Scholar]
  • 22.Hotta N. Advances in Diabetology A Guide to Regimens for Diabetes Mellitus. Shindantochiryo-sha; Tokyo, Japan: 2000. Molecular biology of microangiopathy in diabetes mellitus; pp. 190–224. [in Japanese] [Google Scholar]
  • 23.Hotta N. Advances in Diabetology—A Guide to Regimens for Diabetes Mellitus. Shindantochiryo-sha; Tokyo, Japan: 2000. What account etiologically for angiopathy? Known facts and future tasks; pp. 97–105. [in Japanese] [Google Scholar]
  • 24.Vinki A.I., Pittenger G.L., McNitt P., Stansberry K.B. Diabetic neuropathies: An overview of clinical aspects, pathogenesis, and treatment. In: LeRoith D., Taylor S.I., Olefsky J.M., editors. Diabetes Mellitus: A Fundamental and Clinical Text. 2nd ed. Lippincott Williams & Wilkins; Philadelphia, Pa: 2000. pp. 910–934. [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES